Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 37.9% during trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.20. 640,100 shares changed hands during trading, an increase of 45% from the average session volume of 440,650 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Up 20.0 %
The business has a 50-day simple moving average of C$0.09 and a two-hundred day simple moving average of C$0.07. The stock has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Golden Cross Stocks: Pattern, Examples and Charts
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How Can Investors Benefit From After-Hours Trading
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
